Intercept Pharma (ICPT) Posts Smaller-than-Expected Q2 Loss as Sales Beat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Tech stocks pull Wall Street lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Intercept Pharmaceuticals (ICPT) PT Raised to $221 at BMO Capital on 2Q Report; 'Solid 2Q17 Earnings + Two Positive Phase 2 Readouts... Buy on Weakness'
August 1, 2017 10:21 AM EDTBMO Capital raised its price target on Intercept Pharmaceuticals (NASDAQ: ICPT) to $221.00 (from $218.00) while maintaining a Outperform rating, following the company's second quarter earnings announcement.
Analyst M. Ian Somaiya notes the company delivered second quarter earnings per share and revenue results above consensus... More
Buy Weakness in Intercept (ICPT) - Oppenheimer
July 31, 2017 12:49 PM EDTOppenheimer analyst Jay Olson sees a buying opportunity in Intercept Pharmaceuticals (NASDAQ: ICPT) following weakness in the stock amid concerns about safety and tolerability of OCA in the two studies top-lined following a patient death in the CONTROL study which the investigator and... More
Intercept Pharmaceuticals (ICPT) PT Raised to $69 at Cantor Fitzgerald; 'Can The PBC Growth Trend Persist?'
July 31, 2017 12:04 PM EDTCantor Fitzgerald raised its price target on Intercept Pharmaceuticals (NASDAQ: ICPT) to $69.00 (from $60.00) while maintaining a Underweight rating, following the company's second quarter earnings announcement.
Elemer Piros notes the company delivered second quarter earnings per share and revenues above consensus projections, driven by meaningful... More
